Sermorelin Acetate
Sermorelin is a lab-made peptide that copies the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It has been studied in the growth hormone system, including FDA-era trials as a diagnostic agent and as a treatment for growth hormone deficiency in children.
At a glance
- Hormone-related
- Not yet audited here; the reference library calls it emerging
- 200 mcg per Peptide Dosing Protocols. All 2 sources
- 10 mg in 3 mL
How much to draw
Full calculator →Opened on 200 mcg, the figure Peptide Dosing Protocols reports for Sermorelin Acetate, and a 10 mg vial in 3 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Sermorelin Acetate or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 200-300 mcg · Low: 100 mcg · High: 400-500 mcg | nightly3-6 months · Cycle length Planning note 4 weeks 1 vial 28 nights of 200 mcg from one vial. | subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHideHalf-life: 11-12 minutes. Common dose is 200-300 mcg subQ nightly. |
| 200-300 mcg | Once daily at bedtime, 5 nights per week3-6 months | subcutaneous or oral | Peptide Protocol Wiki |
- nightly3-6 months · Cycle length Planning note 4 weeks 1 vial 28 nights of 200 mcg from one vial.
- subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
Half-life: 11-12 minutes. Common dose is 200-300 mcg subQ nightly.
- Once daily at bedtime, 5 nights per week3-6 months
- subcutaneous or oral
- Peptide Protocol Wiki
- 3 mL bacteriostatic (BAC) water in a 10 mg vial gives 3 units per 100 mcg on a U-100 insulin syringe.
- Bacteriostatic water
We have not published an audit on Sermorelin Acetate. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Sermorelin acts like the brain signal that tells the pituitary, a small gland under the brain, to release a burst of growth hormone. Because it uses the body's own pathway, the natural off-switch hormone somatostatin stays active, so growth hormone rises in pulses instead of staying high, and larger amounts do not always produce a larger pulse. Researchers describe this as binding the GHRH receptor on pituitary somatotroph cells and triggering cAMP signaling inside the cell. Its plasma half-life is about 11 to 12 minutes, and large modern randomized trials in adults are limited after the product was commercially discontinued in 2008, so current adult practice rests on practitioner experience and reviews.
Sermorelin is a small peptide that copies the first 29 amino acids of the body's natural growth hormone-releasing hormone (GHRH). It fits the pituitary gland's GHRH receptor, triggering a normal growth hormone (GH) pulse. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: across 350 patients in the FDA-era pediatric trials, the most common problem was a reaction where the injection was given, such as pain, swelling or redness, in about 17 percent of participants. These were usually mild and usually cleared on their own, and only 3 of the 350 stopped treatment because of them. Each of the following occurred in under 1 percent: headache, facial flushing, trouble swallowing, dizziness, restlessness or hyperactivity, drowsiness, taste changes, hives, and nausea or vomiting. About 70 percent of participants developed anti-GRF antibodies at some point, which the label said did not appear to meaningfully reduce effectiveness or cause reactions in most people, and about 6.5 percent developed an underactive thyroid.
Not ruled out: as with any injected peptide, local or rarely whole-body allergic reactions can occur, including swelling of the face, mouth or throat, trouble breathing, or widespread hives.
Who should avoid it
People with a known allergy to sermorelin or anything in the formulation: listed as a reason not to use it.
People who are pregnant or breastfeeding: the FDA-era label listed it as Pregnancy Category C, there are no controlled studies in pregnant women, and it is unknown whether it passes into breast milk.
People with active cancer: growth hormone and IGF-1 can act as growth signals on cells that are already present, so most protocols screen for active cancer first.
People whose growth hormone deficiency comes from a growth or lesion inside the skull: the FDA-era label said these patients were not studied and were not recommended for sermorelin.
People with an untreated underactive thyroid: this blunts the growth hormone response and is described as something to correct first.
People taking glucocorticoid medicines: the FDA-era label's drug interactions note that these can blunt the response to sermorelin.
What gets monitored
Baseline IGF-1, full thyroid panel, fasting glucose, and comprehensive metabolic panel; follow-up thyroid labs standard due to hypothyroidism risk. (reported by Peptide Dosing Protocols)
Common questions
What amounts are reported for sermorelin?
Reported amounts and schedules for Sermorelin Acetate differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
How much bacteriostatic water do sources describe for a 10 mg sermorelin vial?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Open the reconstitution calculator →How many units would one injection be?
That depends on the vial size and how much bacteriostatic water was added, so no single number applies. Sources do not give a universal unit figure.
What is sermorelin's half-life?
Pooled pharmacokinetic data report a plasma half-life of about 11 to 12 minutes after either intravenous or subcutaneous dosing. Plasma clearance was 2.4 to 2.8 litres per minute, with a rapid peak after injection under the skin.
Is sermorelin FDA-approved?
It was approved twice, in 1990 as a diagnostic agent for growth hormone deficiency and in 1997 as a treatment for childhood growth hormone deficiency under the brand name Geref. As of June 2026 there is no currently marketed FDA-approved product.
Is sermorelin legal to compound in 2026?
Sermorelin remains in FDA 503A Category 1, which allows licensed compounding pharmacies to prepare it. Adult use through compounding pharmacies is off-label.
What are the most common side effects of sermorelin?
The most common was a mild reaction at the injection site, in about 1 in 6 trial participants. Headache, flushing, dizziness, nausea and several others each occurred in under 1 percent.
What changes have been reported with sermorelin?
Reports describe sleep and recovery changes appearing within about 2 to 4 weeks and body-composition changes taking roughly 3 to 6 months. In the FDA-era pediatric program, children had significant increases in growth hormone release and growth speed at 6 months, with results reported through 36 months.
Sources
- 01Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications (2020)
- 02Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging (2006)
- 03Cunha JP. Sermorelin Acetate prescribing information. RxList (FDA-era label content, rev. 10/2/2001) (2022)
- 04U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (503A Category 1 / Category 2 list). FDA.gov (2026)
- 05U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (503A Bulks List review). FDA.gov advisory committee calendar (2026)
- 06Mayo Clinic. Sermorelin (injection route) - side effects and dosage. Mayo Clinic Drugs & Supplements (2025)
- 07DrugBank. Sermorelin (DB00010) drug profile. DrugBank Online (2026)
- 08PubChem. Sermorelin (CID 16132413). PubChem (NCBI) (2026)
- 09Merriam GR, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatrica Supplement (1993)
- 10Frier Levitt Attorneys at Law. Regulatory Status of Peptide Compounding in 2025 (sermorelin and NAD+ as Category 1 examples). Frier Levitt (2026)
- 11ScienceDirect Topics. Sermorelin summary and references. ScienceDirect (Elsevier) (2025)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
This is a combination of two growth hormone compounds sold in a single vial: tesamorelin, a synthetic copy of growth hormone-releasing hormone, and ipamorelin, a ghrelin mimic that acts as a growth hormone secretagogue. It is sold for research use and is studied in the context of the growth hormone system, visceral fat and recovery.
Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.
MOTS-c is a short chain of 16 amino acids that cells build from mitochondrial DNA rather than from the DNA in the nucleus. Most of what is known about it comes from cell and animal work on metabolism, exercise capacity and insulin sensitivity.
Epitalon, also spelled epithalon, is a lab-made peptide of four amino acids (Ala-Glu-Asp-Gly), also called AEDG. It is studied mainly for aging, in cells, in animals and in older non-blinded human work on the related pineal extract.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.
Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.